The new approach would reduce the time and cost of bringing new treatments to patients.
Click here to read the full story in Becker’s Hospital Review on the FDA.
New Draft Regulatory Guidance Would Speed Breast Cancer Drug Approval
The Foundation for the National Institutes of Health announced the release of a draft guidance by the Food and Drug Administration on a new breast cancer drug trial design.
Staying ahead of OBBBA: Tools and strategies to protect patients and strengthen RCM
Recommended Whitepaper